An estimated 17.3 million adults in the United States had at least one major depressive episode; this number represents 7.1% of all U.S. adults. Approximately 35% of adults with major depressive episodes did not receive treatment. In 2017, an estimated 11 million U.S. adults aged 18 or older had at least one major depressive episode with severe impairment. This number represented 4.5% of all U.S. adults.

     Studies have shown that cannabinoids interact with the brain to create antidepressant-like effects. Cannabinol in specific has proven to provide these effects on multiple occasions and continues to do so. Although more research is needed to verify the effects that CBN has on depression, the compound has helped individuals through their depressive episodes and will continue to be studied so that CBN can become a
common solution for individuals who suffer depression.

IMG-2309 (1).PNG

Subscribe to Galileo Labs Inc. For Updates!


  • Amazon
  • Facebook
  • Instagram
  • Twitter
  • LinkedIn

Representations regarding the efficacy and safety of REM have not been evaluated by the Food and Drug Administration.


These products are not intended to diagnose, prevent, treat, or cure any disease. Galileo Labs Inc. uses the highest quality Hemp isolate in product formulations.